ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
Provided By PR Newswire
Last update: Mar 25, 2025
Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models
Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations
Read more at prnewswire.comNYSE:ADCT (9/2/2025, 3:04:03 PM)
3.08
+0.01 (+0.33%)
Find more stocks in the Stock Screener
